Literature DB >> 3990319

The role of cardioplegic solution buffering in myocardial protection. A biochemical and histopathological assessment.

P J del Nido, G J Wilson, D A Mickle, B G Bush, I M Rebeyka, P Klement, R Harding, G A Tait.   

Abstract

The advantages of buffering cardioplegic solutions to improve adenosine triphosphate preservation and postarrest hemodynamic function have been previously promoted. We evaluated the benefit of histidine buffering (195 mmol/L) in a low sodium (27 mEq/L) cardioplegic solution (Roe's) in a canine model of multidose cardioplegic arrest. Four solutions, two unbuffered (K+ = 10 mEq/L and K+ = 30 mEq/L) and two buffered (K+ = 10 mEq/L and K+ = 30 mEq/L), were tested in four groups of dogs for a 4 1/2 hour arrest period followed by 1 hour of reperfusion. Use of the unbuffered solution resulted in a drop in myocardial adenosine triphosphate from 29 +/- 1 mmol/kg (mean +/- standard error of the mean) (K+ = 30 mEq/L) and 28 +/- 2 mmol/kg (K+ = 10 mEq/L) to 8 +/- 2 mmol/kg and 7 +/- 2 mmol/kg, respectively, during the arrest period. In both buffered groups, adenosine triphosphate remained at preischemic levels during the entire arrest period. Myocardial glycogen followed the same pattern as adenosine triphosphate in the buffered groups. Lactate production was markedly elevated in all groups during ischemia. Postarrest hemodynamic function, as assessed by intraventricular isovolumic developed pressure measurements, was better (p less than 0.05) in the buffered low-potassium group than in the other three groups. The extent of myocardial necrosis, measured by triphenyl tetrazolium staining and confirmed by electron microscopy, was minimal (2% +/- 1% of biventricular mass) in the buffered low-potassium group, significantly greater (7% +/- 2% and 10% +/- 2%) in the unbuffered high-potassium and low-potassium groups, respectively, and highest (35% +/- 9%) in the buffered high-potassium group. These findings indicate that significant buffering capacity (similar to that of blood) in a crystalloid cardioplegic solution can be effective in preserving myocardial adenosine triphosphate stores, improving postarrest contractile function, and minimizing myocardial necrosis, provided the combination of high extracellular potassium and high pH levels is avoided.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3990319

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  New insights on the use of del Nido cardioplegia in the adult cardiac surgery.

Authors:  Paolo Nardi; Calogera Pisano; Fabio Bertoldo; Giovanni Ruvolo
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  History and use of del Nido cardioplegia solution at Boston Children's Hospital.

Authors:  Gregory S Matte; Pedro J del Nido
Journal:  J Extra Corpor Technol       Date:  2012-09

3.  Feasibility and safety of continuous retrograde administration of Del Nido cardioplegia: a case series.

Authors:  Marc Najjar; Isaac George; Hirokazu Akashi; Takashi Nishimura; Halit Yerebakan; Linda Mongero; James Beck; Stephen C Hill; Hiroo Takayama; Mathew R Williams
Journal:  J Cardiothorac Surg       Date:  2015-11-26       Impact factor: 1.637

4.  Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.

Authors:  X W Li; Y Z Lin; H Lin; J B Huang; X M Tang; X M Long; W J Lu; Z K Wen; J Liang; D Y Li; X F Zhao
Journal:  Braz J Med Biol Res       Date:  2016-05-13       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.